Login / Signup

Radioiodine treatment for graves' disease: a 10-year Australian cohort study.

Erin FanningWarrick J InderEmily Mackenzie
Published in: BMC endocrine disorders (2018)
Radioiodine is an effective therapy for Graves' Disease with few complications. The majority of patients achieve remission with a single dose. Those who require a second dose are more likely to have higher TSH receptor antibody titres at diagnosis. To the best of our knowledge, this is the first study to report outcomes from radioiodine treatment for Graves' disease in an Australian population.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • healthcare
  • newly diagnosed
  • chronic kidney disease
  • peritoneal dialysis
  • rheumatoid arthritis
  • prognostic factors
  • patient reported outcomes